3.11
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
Revenues |
8.96%
62.47
|
57.34 | 46.50 | 37.43 | 43.65 |
Cost Of Revenue |
30.09%
9.919
|
7.625 | 20.36 | 14.16 | 17.05 |
Gross Profit |
5.72%
52.55
|
49.71 | 26.13 | 23.27 | 26.60 |
|
6.26%
38.46
|
36.20 | 40.44 | 35.77 | 35.33 |
Benefits Costs and Expenses |
21.48%
62.23
|
51.22 | 69.30 | 57.47 | 52.23 |
Costs And Expenses |
21.48%
62.23
|
51.22 | 69.30 | 57.47 | 52.23 |
Operating Income/Loss |
4.25%
14.09
|
13.51 | -14.31 | -12.51 | -8.725 |
Income/Loss From Continuing Operations Before Tax |
95.96%
0.247
|
6.112 | -22.80 | -20.04 | -8.582 |
Income/Loss From Continuing Operations After Tax |
95.96%
0.247
|
6.112 | -22.80 | -20.04 | -8.582 |
|
95.96%
0.247
|
6.112 | -22.80 | -20.04 | -8.582 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
11.49%
262.57
|
235.50 | 2.603 | 210.35 | 209.71 |
Diluted Average Shares |
12.21%
271.10
|
241.60 | 2.603 | 210.35 | 209.71 |
Basic Earnings Per Share |
100.00%
-
|
0.03 | -0.11 | -0.10 | -0.04 |
Diluted Earnings Per Share |
100.00%
-
|
0.03 | -0.11 | -0.10 | -0.04 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):